• 1
    Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol. 2005; 34: 405-412.
  • 2
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
  • 3
    Green M, Raina V. Epidemiology, screening and diagnosis of breast cancer in the Asia-Pacific region: current perspectives and important considerations. Asian Pac J Clin Oncol. 2008; 4( suppl 3): S5-S13.
  • 4
    Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009; 27: 1323-1333.
  • 5
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-182.
  • 6
    Di Cosimo S, Baselga J. Targeted therapies in breast cancer: where are we now? Eur J Cancer. 2008; 44: 2781-2790.
  • 7
    Kwan ML, Kushi LH, Weltzien E, et al. Epidemiology of breast cancer subtypes in 2 prospective cohort studies of breast cancer survivors [serial online]. Breast Cancer Res. 2009; 11: R31.
  • 8
    Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009; 5: 593-602.
  • 9
    Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118-145.
  • 10
    Chearskul S, Onreabroi S, Churintrapun M, Semprasert N, Bhothisuwan K. Immunohistochemical study of c-erbB-2 expression in primary breast cancer. Asian Pac J Allergy Immunol. 2001; 19: 197-205.
  • 11
    Chen SC, Chang HK, Lin YC, et al. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin. Jpn J Clin Oncol. 2008; 38: 99-105.
  • 12
    Fernandopulle SM, Cher-Siangang P, Tan PH. Breast carcinoma in women 35 years and younger: a pathological study. Pathology. 2006; 38: 219-222.
  • 13
    Huang MY, Wang YH, Chen FM, et al. Multiple genetic polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC highly correlated with early relapse of breast cancer patients in Taiwan. Ann Surg Oncol. 2008; 15: 872-880.
  • 14
    Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006; 37: 1217-1226.
  • 15
    Lin CH, Liau JY, Lu YS, et al. Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just Westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1807-1814.
  • 16
    Lin YC, Chang HK, Chen JS, Wang HM, Yang TS, Liaw CC. A phase II randomized study of 2 taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis. Jpn J Clin Oncol. 2007; 37: 23-29.
  • 17
    Meenakshi A, Kumar RS, Ganesh V, Sivakumar N. Immunohistochemical assay (IHC) to study C-erbB-2 status of breast cancer using monoclonal antibody CIBCgp185. Hum Antibodies. 2003; 12: 123-127.
  • 18
    Park K, Han S. A single institute's experience of standardization for the HER2 status by fluorescence in situ hybridization and immunohistochemistry on a primary breast cancer tissue microarray. J Kor Breast Cancer Soc. 2004; 7: 27-31.
  • 19
    Park K, Kim JS, Lim S, Han S, Lee JY. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mol Pathol. 2003; 16: 937-943.
  • 20
    Selvarajan S, Tan SY, Sii LH, Tan PH. c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: is there concordance between standard sections and tissue microarrays? Pathology. 2006; 38: 316-320.
  • 21
    Selvarajan S, Wong KY, Khoo KS, Bay BH, Tan PH. Over-expression of c-erbB-2 correlates with nuclear morphometry and prognosis in breast carcinoma in Asian women. Pathology. 2006; 38: 528-533.
  • 22
    Shin HJ, Han W, Kim SW, et al. Postoperative survival and prognostic factors in breast cancer: a single center analysis of 4,063 cases. J Breast Cancer. 2006; 9: 55-60.
  • 23
    Tan BK, Tan LK, Yu K, et al. Clinical validation of a customized multiple signature microarray for breast cancer. Clin Cancer Res. 2008; 14: 461-469.
  • 24
    The Korean Breast Cancer Society. Nationwide Korean breast cancer data of 2004 using breast cancer registration program. J Breast Cancer. 2006; 9: 151-161.
  • 25
    Tsai KB, Hou MF, Lin HJ, Chai CY, Liu CS, Huang TJ. Expression of HER-2/NEU oncoprotein in familial and non-familial breast cancer. Kaohsiung J Med Sci. 2001; 17: 64-76.
  • 26
    Zhang D, Salto-Tellez M, Do E, Putti TC, Koay ES. Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol. 2003; 34: 362-368.
  • 27
    Bhamrah R, Julka PK, Nair O, et al. Correlations between epidermal growth factor receptor, Her-2-neu and estrogen receptor in carcinoma breast: a study from cancer centre in India [abstract]. J Clin Oncol. 2008; 26. May 20 suppl).Abstract 22173.
  • 28
    Moohamad H, Satthaporn S, Supaporn S, Asanprakit W, Vassanasiri W. Are there any differences in the characteristics of breast cancer with regards to its HER-2/NEU status? Paper presented at: 33rd Annual Scientific Meeting of the Royal College of Surgeons of Thailand; July 17-20, 2008; Pattaya, Thailand.
  • 29
    Sanchez MTK, Yeo AT, Gorospe CV, et al. HER-2/neu overexpression among Filipino patients with breast cancer: a 10 year review. Paper presented at: 10th International Conference on Primary Therapy of Early Breast Cancer; March 14-17, 2008; St. Gallen, Switzerland.
  • 30
    Shahrun NS, Rohaizak M, Naqiyal I, Shamsul AS. Breast cancer subtypes and its correlation: a retrospective single centre study. Paper presented at: 11th Congress of the Asian Association of Endocrine Surgeons and Annual Scientific Meeting of the College of Surgeons; March 20-22, 2008; Sabah, Malaysia.
  • 31
    Tan GH, Yip CH. Association between tumour characteristics and HER2/neu by immuno-histochemistry in 393 women with breast cancer. Paper presented at: 11th Congress of the Asian Association of Endocrine Surgeons and Annual Scientific Meeting of the College of Surgeons; March 20-22, 2008; Sabah, Malaysia.
  • 32
    Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002; 77-154. 148-154.
  • 33
    Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004; 291: 1972-1977.
  • 34
    Chow LWC, Im Y-H. Current treatment of locally advanced and metastatic breast cancer in the Asia-Pacific region: challenges and limitations. Asia-Pacific J Clin Oncol. 2008; 4: S14-S23.
  • 35
    Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg. 2007; 31: 1031-1040.
  • 36
    Lim SE, Back M, Quek E, Iau P, Putti T, Wong JE. Clinical observations from a breast cancer registry in Asian women. World J Surg. 2007; 31: 1387-1392.
  • 37
    Shyyan R, Masood S, Badwe RA, et al. Breast cancer in limited-resource countries: diagnosis and pathology. Breast J. 2006; 12: S27-S37.
  • 38
    Sharifah NA, Lee BR, Clarence-Ko CH, et al. C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre. Asian Pac J Cancer Prev. 2008; 9: 663-670.
  • 39
    Nakajima H, Fujiwara I, Mizuta N, et al. Prognosis of Japanese breast cancer based on hormone receptor and HER2 expression determined by immunohistochemical staining. World J Surg. 2008; 32: 2477-2482.
  • 40
    Kurebayashi J, Moriya T, Ishida T, et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast. 2007; 16: S72-S77.
  • 41
    Cao W, Zhang B, Liu Y, et al. High-level SLP-2 expression and HER-2/neu protein expression are associated with decreased breast cancer patient survival. Am J Clin Pathol. 2007; 128: 430-436.